Our data demonstrate that clinical application of PDK inhibitors against chronic hepatitis C could reduce the required dosage of PEGylated IFN-α, thereby ameliorating or abolishing adverse effects. This evidence concerns the gene IFNA1 and chronic hepatitis C virus infection.